Mesenteric approach is an artery-first approach during pancreaticoduodenectomy (PD). In the present study, we evaluated clinical and oncological benefits of this procedure for pancreatic ductal adenocarcinoma (PDAC) of the pancreas head.
| INTRODUCTION
In spite of advanced radiographic images, surgical techniques, and chemo(radiation) therapies, the survival rate for pancreatic ductal adenocarcinoma (PDAC) patients is still dismal. Curative treatment for PDAC is considered to be surgical resection only with negative surgical margins (R0) and adjuvant therapies. PDAC tumors without distant metastases were classified into resectable (R-), borderline resectable (BR-), and unresectable PDAC, based on the degree of involvement of the portal vein and/or the superior mesenteric vein (PV/SMV) or major arteries, according to the National Comprehensive Cancer Network (NCCN) 1 and General Rules for the Study of Pancreatic Cancer, 7th
edition by the Japanese Pancreatic Society (JPS). 2 Pathological positive margins of resected specimens (R1) could be found not only in BR-PDAC but also in R-PDAC, and might lead to early recurrence and poor survival. Dissected margins around the superior mesenteric artery (SMA) have been specifically reported to be the most favorable R1 site for PDAC located in the pancreatic head. [3] [4] [5] [6] Since the 'artery-first approach' during pancreaticoduodenectomy (PD) was reported in 2010, 7 this term has spread worldwide. The concept of the artery-first approach is to start from the dissection of the connective tissues around the SMA during PD. The aims of this approach are: (i) early determination of the resectability status before committing an irreversible step during operation; (ii) reduction of intraoperative blood loss by early control of blood inflow into the pancreatic head; and (iii) increase of R0 rates by complete dissection of the connected tissues around the SMA.
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The 'mesenteric approach', first reported by Nakao and Takagi   8 in 1993, is one artery-first approach and is synonymous with the 'infracolic approach'. 11 This approach allows dissection around the SMA from the noncancerous or less inflammatory side at the mesenterium, around the root of the middle colic artery (MCA). 8, 9, 12, 14 Therefore, one should consider that the mesenteric approach may be a safer procedure than other approaches during PD. However, as there have been only a small number of case series reporting the feasibility of the mesenteric approach, 8, 9, 12, 14 evidence for the clinical and oncological benefits of this approach is sparse. In the present study, we evaluated the clinical and oncological outcomes of the mesenteric approach during PD for PDAC of the pancreatic head by comparison with the conventional approach.
2 | ME TH ODS After lifting the transverse colon cranially, the mesenterium was incised from the Treitz ligament to the inferior duodenal flexure to identify the SMA and SMV. 12 The MCA was exposed arising from the anterior side of the SMA, and this artery was usually divided. After the stomach was divided, lymphadenectomy around the CHA (#8) and root of the left gastric artery (#7), left side of the celiac axis (#9), and in the hepatoduodenal ligament (#12) was carried out.
After division of the bile duct, the gastroduodenal artery (GDA) was then ligated and divided. The pancreas was transected, and the pancreas head was abraded from the PV. Finally, the bundle tissues, including nerve plexus, lymph node, and vessels, between the celiac axis and the dorsal surface of the pancreas head were dissected, identified as pancreatic head plexus I (plPh-I) by the JPS. 2 The jejunum was divided, and the tumor with en bloc dissected tissues was removed. If tumor invasion of the PV/SMV was suspected pre-and/or intraoperatively, concomitant resection was carried out immediately before the specimen was removed and reconstruction of PV/SMV. 17 After removal of the specimen, pancreaticojejunostomy, choledochojejunostomy, and gastrojejunostomy were carried out in turn.
| Conventional approach
Following Kocher's maneuver, Henle's gastrocolic trunk was divided. After the stomach or duodenum was divided, lymphadenectomy around the same areas as those of the mesenteric approach (#7, #8, #9, and #12) and division of the bile duct were done. The GDA was then divided and the pancreas was transected.
The pancreatic head was abraded from the PV/SMV. Finally, exerting traction on the pancreatic head to the right, the plPh-I was dissected from the celiac axis and plPh-II tissues were dissected from the SMA, and the IPDA was divided at this step. After complete isolation of the pancreatic head from the SMA, the jejunum was transected and the specimen was removed. The same reconstruction as that of the mesenteric approach was then carried out.
| Definitions of morbidity and mortality and pathological diagnosis
Criterion for intraoperative transfusion is a hemoglobin value less than 8.0 g/dL and change in vital signs, including low blood pressure and tachycardia, during operation. consecutive days followed by a 7-day rest for 6 months.
Patients were followed postoperatively as follows; CT was done every 3 months during postoperative year 1 and every 6 months thereafter. Overall survival (OS) was defined as the time interval from the date of surgery or initial neoadjuvant therapy to either death or the last follow-up date. Recurrence was defined as convincing radiographic evidence of disease during postoperative follow up and was histologically confirmed when possible. Disease-free survival (DFS) was defined as the time interval from the date of surgery to diagnosis of recurrence.
| Statistical analysis
Summary statistics were calculated with medians and ranges for continuous variables, and frequencies and proportions for categorical variables. Chi-squared tests and Mann-Whitney U-test were used to assess differences between treatment groups (mesenteric and conventional groups) and patient characteristics.
Our estimation was a propensity score using a multiple logistic regression model with four covariates: age, gender, resectability status, neoadjuvant therapy. Nearest neighbor paired matching was used to reduce bias resulting from possible imbalance in observed covariates between mesenteric and conventional groups.
Matched patients were evaluated for differences between treatment groups in each of the post-operative factors. Moreover, OS and DFS were estimated by the Kaplan-Meier method and they were compared using the log-rank test. When we compared patients' characteristics between mesenteric and conventional groups in unmatched-pairs analysis (Table 1) , the incidence of neoadjuvant therapy was higher in the mesenteric group than in the conventional group, although significant differences in other background factors were not found.
In matched-pairs analysis after matching for age, gender resectability status, and administration of neoadjuvant therapy, there were no significant differences in all background factors between the two groups ( There were no significant differences in morbidity rates, including pancreatic fistula and DGE, and mortality rates and in the frequency of initial administration of adjuvant therapy within 8 weeks after PD between the two groups in both R-and BR-PDAC in unmatchedand matched-pairs analyses (Tables 3 and 4) . Numbers of harvested or metastatic lymph nodes were similar between the two groups in R-and BR-PDAC in both analyses (Tables 3 and 4) . However, the rate of R0 resection was significantly higher in the mesenteric group in R-PDAC patients in both unmatched-and matched-pairs analyses (unmatched: 100% vs 87.7%, P=.044 and matched: 100% vs 86.7%, P=.045), although there were no significant differences in the R0 rate in BR-PDAC in both analyses.
Incidence of postoperative recurrence was similar in both R-and BR-PDAC patients in matched-pairs analysis, although all recurrence rates and local recurrence rates in R-PDAC patients were lower in the mesenteric group in unmatched-pairs analysis (all recurrence:
53.3% vs 77.8%, P=.012, local recurrence: 16.7% vs 38.3%, P=.031, Figure 2 ). OS was longer in the mesenteric group than in the conventional group in R-PDAC patients in both unmatched-and matched-pairs analyses (unmatched: P=.008, Figure 3A , matched:
P=.021, Figure 3B ), although there were no significant differences in DFS between the two groups in R-PDAC patients in both analyses.
In BR-PDAC patients, OS and DFS were similar in the two groups in both analyses ( Figure 3C, D) .
| Identification of risk factors for poor survival for R-PDAC and BR-PDAC patients
We investigated the risk factors associated with poor OS and DFS in all R-PDAC (n=111) or BR-PDAC patients (n=126). In R-PDAC patients, we found six factors for poor OS on univariate analysis: F I G U R E 2 Recurrence rates of resectable pancreatic ductal adenocarcinoma (R-PDAC) and borderline resectable PDAC (BR-PDAC) patients in unmatched-and matched-pairs analyses. All recurrence rates and local recurrence rates were significantly lower in the mesenteric group than in the conventional group in unmatched-pairs analysis only (*all recurrence: 53.3% vs 77.8%, P=.012; **local recurrence: 16.7% vs 38.3%, P=.031).
were independent risk factors. Regarding DFS in R-PDAC patients, we found four risk factors for poor DFS on univariate analysis; jaun- 
| DISCUSSION
Connective tissue between the pancreatic head and the SMA plexus has been defined as pancreatic head plexus II (plPh-II), but is also known as 'mesopancreas' 10,21,22 or 'meso-pancreatoduodenum'.
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F I G U R E 3 (A) Overall survival (OS) for resectable pancreatic ductal adenocarcinoma (R-PDAC) patients in unmatched-pairs analysis was longer in the mesenteric group than in the conventional group (P=.008), although the disease-free survival (DFS) was similar in the two groups. (B) OS for R-PDAC patients in matched-pairs analysis was also longer in the mesenteric group than in the conventional group (P=.021), although there was no significant difference of DFS. (C) There were no significant differences of both OS and DFS in borderline resectable PDAC (BR-PDAC) patients in unmatched-pairs analysis. (D) There were no significant differences of both OS and DFS in BR-PDAC patients in matched-pairs analysis.
However, from an anatomical point of view, this nomenclature is controversial. 24 The dissected margin of plPh-II is reported to be the most favorable positive margin site for PDAC of the pancreatic head. [3] [4] [5] [6] Therefore, complete clearance of the connective tissue around the SMA during PD is considered to increase R0 rate and improve the survival rate of patients with PDAC located in the pancreatic head. [8] [9] [10] 12, 13, [21] [22] [23] 25 Furthermore, the artery-first approach aims to assess resectability status before irreversible steps in the operation and reduce blood loss as a result of early ligation of the vessels to the pancreatic head. However, a limited case series that reported the feasibility of the artery-first approach during PD has found little evidence of the availability and/or oncological benefits of this procedure. 10, 13, 14, 23, 24 The mesenteric approach, which is one of the artery-first approaches during PD, 8, 9, 12 is considered to be a safer procedure because, in this approach, dissection around the SMA starts from an infracolic noncancerous and/or no inflammatory region toward the root of the SMA. Therefore, since 2011, we have carried out the mesenteric approach for PDAC. In the present study, we evaluated the perioperative and oncological outcomes of this approach compared with those of the conventional approach.
When we compared the backgrounds of the mesenteric and conventional groups, the rate of administration of neoadjuvant therapy was significantly higher in the mesenteric group, as a result of the different time periods of each approach. Therefore, we selected 58 patients with the mesenteric approach and 58 patients with the conventional approach based on a 1:1 matching scheme based on age, gender, resectability status, and administration of neoadjuvant therapy. We had to consider factors that may have had an implication for perioperative and oncological outcomes in order to remove background bias of the two groups. We compared the clinicopathological features between the two groups in both unmatched-and matchedpairs analyses.
Regarding perioperative outcome, we found that operative time was longer in the mesenteric group than in the conventional group in R-PDAC, and the volume of intraoperative blood loss was lower in both R-PDAC and BR-PDAC, and the incidence of transfusion
was lower in BR-PDAC in both unmatched-and matched-pairs analyses. The reason for the longer time in the mesenteric group may be associated with the learning curve of operation. Our results indicate that the mesenteric approach might reduce intraoperative blood loss by early ligation of vessels flowing into the pancreatic head, and it may lead to a decrease in the incidence of transfusion.
Although we found that the frequency of postoperative complications was similar in the two groups, the length of the hospital stay was shorter in the mesenteric group in R-PDAC patients. The frequencies of administration of adjuvant therapy within 8 weeks after surgery and completion of the planned postoperative adjuvant therapy were not different in the two groups in both matched R-PDAC and BR-PDAC patients. However, the regimens of postoperative adjuvant therapy in the mesenteric and conventional groups were different even in matched-pairs analyses, in which gemcitabine was dominant for the conventional group and S-1 was dominant for the mesenteric group (R-PDAC; P=.002 and BR-PDAC; P=.080), and this historical bias is a huge problem for survival analysis in the present study.
Regarding oncological outcome, we found that the R0 rate was higher in the mesenteric group than in the conventional group in R-PDAC patients. However, there was no significant difference between the two groups in BR-PDAC patients in unmatched-and matched-pairs analyses. These results indicated that the mesenteric approach for R-PDAC in the pancreatic head might increase R0 rate by complete dissection of connective tissues around the SMA, and this procedure might lead to improvement of survival for R-PDAC patients. However, in the present study, the mesenteric approach alone could not improve the R0 rate as well as the survival of BR-PDAC patients. Therefore, one should consider that effective neoadjuvant therapy may be necessary to increase the R0 rate, and multi- we plan to start this RCT soon.
In conclusion, the mesenteric approach might reduce blood loss during PD by early ligation of vessels to the pancreatic head in both R-and BR-PDAC patients, leading to low frequency of 
